Format
Sort by
Items per page

Send to

Choose Destination

Best matches for dapagliflozin AND diabetes mellitus, non-insulin-dependent AND hemoglobin a AND insulin:

Search results

Items: 1 to 20 of 34

1.

SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study.

Tamez-Perez HE, Delgadillo-Esteban E, Soni-Duque D, Hernández-Coria MI, Tamez-Peña AL.

J Diabetes Metab Disord. 2017 Jun 30;16:27. doi: 10.1186/s40200-017-0308-4. eCollection 2017.

2.

New Oral Hypoglycemic Agents and Cardiovascular Risk. Crossing the Metabolic Border.

Dalama B, Mesa J.

Rev Esp Cardiol (Engl Ed). 2016 Nov;69(11):1088-1097. doi: 10.1016/j.rec.2016.07.008. Epub 2016 Sep 26. Review. English, Spanish.

PMID:
27687335
3.

Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16-week double-blind treatment period.

Araki E, Onishi Y, Asano M, Kim H, Ekholm E, Johnsson E, Yajima T.

J Diabetes Investig. 2016 Jul;7(4):555-64. doi: 10.1111/jdi.12453. Epub 2016 Jan 22.

4.

Dapagliflozin in the treatment of patients with type 2 diabetes presenting with high baseline A1C.

Skolnik N, Bonnes H, Yeh H, Katz A.

Postgrad Med. 2016 May;128(4):356-63. doi: 10.1080/00325481.2016.1173514. Epub 2016 Apr 18.

PMID:
27043045
5.

Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study.

Weber MA, Mansfield TA, Cain VA, Iqbal N, Parikh S, Ptaszynska A.

Lancet Diabetes Endocrinol. 2016 Mar;4(3):211-20. doi: 10.1016/S2213-8587(15)00417-9. Epub 2015 Nov 27. Erratum in: Lancet Diabetes Endocrinol. 2016 Mar;4(3):e3.

PMID:
26620248
6.

Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus.

Fioretto P, Giaccari A, Sesti G.

Cardiovasc Diabetol. 2015 Oct 17;14:142. doi: 10.1186/s12933-015-0297-x. Review.

7.

Combination therapy with saxagliptin and dapagliflozin for the treatment of type 2 diabetes.

Williams DM, Stephens JW.

Expert Opin Pharmacother. 2015;16(15):2373-9. doi: 10.1517/14656566.2015.1088830. Review.

PMID:
26389773
8.

The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes.

Whalen K, Miller S, Onge ES.

Clin Ther. 2015 Jun 1;37(6):1150-66. doi: 10.1016/j.clinthera.2015.03.004. Epub 2015 Apr 16. Review.

PMID:
25891804
9.

Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension.

Cefalu WT, Leiter LA, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ.

Diabetes Care. 2015 Jul;38(7):1218-27. doi: 10.2337/dc14-0315. Epub 2015 Apr 7.

10.

Sodium-glucose cotransporter 2 inhibitors: the new option for diabetes mellitus management.

Powell J, Miller SA, Taylor JR.

South Med J. 2015 Feb;108(2):82-90. doi: 10.14423/SMJ.0000000000000233. Review.

PMID:
25688892
11.

Estimating Cost-Effectiveness in Type 2 Diabetes: The Impact of Treatment Guidelines and Therapy Duration.

McEwan P, Gordon J, Evans M, Ward T, Bennett H, Bergenheim K.

Med Decis Making. 2015 Jul;35(5):660-70. doi: 10.1177/0272989X14565821. Epub 2015 Jan 16.

PMID:
25596535
12.

Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time.

Parikh S, Wilding J, Jabbour S, Hardy E.

Int J Clin Pract. 2015 Feb;69(2):186-98. doi: 10.1111/ijcp.12531. Epub 2014 Nov 28.

PMID:
25438821
13.

Dapagliflozin: a review of its use in patients with type 2 diabetes.

Plosker GL.

Drugs. 2014 Dec;74(18):2191-209. doi: 10.1007/s40265-014-0324-3. Review.

PMID:
25389049
14.

The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.

Lajara R.

Expert Opin Pharmacother. 2014 Dec;15(17):2565-85. doi: 10.1517/14656566.2014.968551. Epub 2014 Oct 15. Review.

PMID:
25316597
15.

Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: systematic review and meta-analyses.

Zhang Q, Dou J, Lu J.

Diabetes Res Clin Pract. 2014 Sep;105(3):313-21. doi: 10.1016/j.diabres.2014.06.006. Epub 2014 Jun 22. Review.

PMID:
25015317
16.

[Dapagliflozin, the first SGLT-2 inhibitor in the treatment of type 2 diabetes].

Albarrán OG, Ampudia-Blasco FJ.

Med Clin (Barc). 2013 Sep;141 Suppl 2:36-43. doi: 10.1016/S0025-7753(13)70062-9. Review. Spanish.

PMID:
24444523
17.

Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes.

Dziuba J, Alperin P, Racketa J, Iloeje U, Goswami D, Hardy E, Perlstein I, Grossman HL, Cohen M.

Diabetes Obes Metab. 2014 Jul;16(7):628-35. doi: 10.1111/dom.12261. Epub 2014 Feb 19.

PMID:
24443793
18.

Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials.

Monami M, Nardini C, Mannucci E.

Diabetes Obes Metab. 2014 May;16(5):457-66. doi: 10.1111/dom.12244. Epub 2013 Dec 29.

PMID:
24320621
19.

Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin.

Mudaliar S, Henry RR, Boden G, Smith S, Chalamandaris AG, Duchesne D, Iqbal N, List J.

Diabetes Technol Ther. 2014 Mar;16(3):137-44. doi: 10.1089/dia.2013.0167. Epub 2013 Nov 15.

PMID:
24237386
20.

Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.

Wilding JP, Woo V, Rohwedder K, Sugg J, Parikh S; Dapagliflozin 006 Study Group.

Diabetes Obes Metab. 2014 Feb;16(2):124-36. doi: 10.1111/dom.12187. Epub 2013 Aug 29.

PMID:
23911013

Supplemental Content

Loading ...
Support Center